Potent, long-acting cyclopentane-1,3-dione thromboxane (A2)-receptor antagonists

ACS Medicinal Chemistry Letters

Volumn 5, Issue 9, 2014, Pages 1015-1020

  Wang, Xiaozhao ^a   Liu, Li ^b   Huang, Longchuan ^a   Herbst Robinson, Katie ^b   Cornec, Anne Sophie ^a   James, Michael J ^b   Sugiyama, Shimpei ^a   Bassetto, Marcella ^c   Brancale, Andrea ^c   Trojanowski, John Q ^b   Lee, Virginia M Y ^b   Smith, Amos B ^a   Brunden, Kurt R ^b   Ballatore, Carlo ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

carboxylic acid bioisostere; Cyclopentane 1,3 dione; thromboxane A2; thromboxane receptor antagonists

Indexed keywords

3 [3 [2 [(4 CHLOROPHENYL)SULFONAMIDO]ETHYL]PHENYL]PROPANOIC ACID; 3 [6 [(4 CHLOROPHENYL)SULFONAMIDO] 5,6,7,8 TETRAHYDRONAPHTHALEN 1 YL]PROPANOIC ACID; ALICYCLIC COMPOUND; CARBOXYLIC ACID; CYCLOPENTANE 1,3 DIONE; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS;

EID: 84907527298     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5002085     Document Type: Article

References (23)

1. Hamberg, M.; Svensson, J.; Samuelsson, B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides Proc. Natl. Acad. Sci. U S A 1975, 72, 2994-2998
2. Nakahata, N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology Pharmacol. Ther. 2008, 118, 18-35
3. Smyth, E. M. Thromboxane and the thromboxane receptor in cardiovascular disease Clin. Lipidol. 2010, 5, 209-219
4. Dogne, J. M.; Hanson, J.; de Leval, X.; Pratico, D.; Pace-Asciak, C. R.; Drion, P.; Pirotte, B.; Ruan, K. H. From the design to the clinical application of thromboxane modulators Curr. Pharm. Des. 2006, 12, 903-923
5. Ting, H. J.; Murad, J. P.; Espinosa, E. V.; Khasawneh, F. T. Thromboxane A2 receptor: biology and function of a peculiar receptor that remains resistant for therapeutic targeting J. Cardiovasc. Pharmacol. Ther. 2012, 17, 248-259
6. Lee, M.; Ovbiagele, B. Vascular events after stroke: terutroban fails to PERFORM Lancet 2011, 377, 1980-1982
7. Cimetiere, B.; Dubuffet, T.; Muller, O.; Descombes, J. J.; Simonet, S.; Laubie, M.; Verbeuren, T. J.; Lavielle, G. Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists Bioorg. Med. Chem. Lett. 1998, 8, 1375-1380
8. Bousser, M. G.; Amarenco, P.; Chamorro, A.; Fisher, M.; Ford, I.; Fox, K.; Hennerici, M.; Mattle, H. P.; Rothwell, P. M.; Investigators, P. S. The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population Cerebrovasc. Dis. 2009, 27, 608-613
9. Ekambaram, P.; Lambiv, W.; Cazzolli, R.; Ashton, A. W.; Honn, K. V. The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis Cancer Metastasis Rev. 2011, 30, 397-408
10. Shineman, D. W.; Zhang, B.; Leight, S. N.; Pratico, D.; Lee, V. M. Y. Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 Mice J. Neurosci. 2008, 28, 4785-4794
11. Dickinson, R. P.; Dack, K. N.; Long, C. J.; Steele, J. Thromboxane modulating agents. 3. 1 H -Imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists J. Med. Chem. 1997, 40, 3442-3452
12. Ballatore, C.; Soper, J. H.; Piscitelli, F.; James, M.; Huang, L.; Atasoylu, O.; Huryn, D. M.; Trojanowski, J. Q.; Lee, V. M.; Brunden, K. R.; Smith, A. B. Cyclopentane-1,3-dione: a novel isostere for the carboxylic acid functional group. Application to the design of potent thromboxane (A2) receptor antagonists J. Med. Chem. 2011, 54, 6969-6983
13. Soper, J. H.; Sugiyama, S.; Herbst-Robinson, K.; James, M. J.; Wang, X.; Trojanowski, J. Q.; Smith, A. B., III; Lee, V. M.; Ballatore, C.; Brunden, K. R. Brain-penetrant tetrahydronaphthalene thromboxane A2-prostanoid (TP) receptor antagonists as prototype therapeutics for Alzheimers disease ACS Chem. Neurosci. 2012, 3, 928-940
14. Cimetiere, B.; Dubuffet, T.; Landras, C.; Descombes, J. J.; Simonet, S.; Verbeuren, T. J.; Lavielle, G. New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors Bioorg. Med. Chem. Lett. 1998, 8, 1381-1386
15. Dogne, J. M.; Hanson, J.; Leval, X.; Pratico, D.; Pace-Asciak, C. R.; Drion, P.; Pirotte, B.; Ruan, K. H. From the design to the clinical application of thromboxane modulators Curr. Pharm. Des. 2006, 12, 903-923
16. Sorbera, L. A.; Serradell, N.; Bolos, J.; Bayes, M. Terutroban sodium. Prostanoid TP receptor antagonist, antithrombotic agent, antiatherosclerotic agent Drugs Future 2006, 31, 867-873
17. Smith, A. J.; Zhang, X.; Leach, A. G.; Houk, K. N. Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins J. Med. Chem. 2009, 52, 225-233
18. Yamamoto, Y.; Kamiya, K.; Terao, S. Modeling of human thromboxane A2 receptor and analysis of the receptor-ligand interaction J. Med. Chem. 1993, 36, 820-825
19. Ma, J. C.; Dougherty, D. A. The cation-π interaction Chem. Rev. 1997, 97, 1303-1324
20. Dougherty, D. A. Cation-π interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp Science 1996, 271, 163-168
21. Hiraga, K. Structures of cyclopentanepolyones Chem. Pharm. Bull. 1965, 13, 1300-1306
22. Trainor, G. L. The importance of plasma protein binding in drug discovery Expert Opin. Drug Discovery 2007, 2, 51-64
23. Van der Graaf, P. H.; Stam, W. B.; Saxena, P. R. Benextramine acts as an irreversible noncompetitive antagonist of U46619-mediated contraction of the rat small mesenteric artery Eur. J. Pharmacol. 1996, 300, 211-214